Avenue Therapeutics, Inc. Common Stock
ATXI
ATXI was delisted on the 18th of March, 2025.
30 hedge funds and large institutions have $11.1M invested in Avenue Therapeutics, Inc. Common Stock in 2021 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 8 increasing their positions, 5 reducing their positions, and 6 closing their positions.
60% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 5
9% less capital invested
Capital invested by funds: $12.2M → $11.1M (-$1.09M)
9% less funds holding
Funds holding: 33 → 30 (-3)
50% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$240K |
| 2 |
Goldman Sachs
New York
|
+$103K |
| 3 |
TI
Trexquant Investment
Stamford,
Connecticut
|
+$82.5K |
| 4 |
Squarepoint
New York
|
+$68.7K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$48.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.47M |
| 2 |
Morgan Stanley
New York
|
-$151K |
| 3 |
VF
Virtu Financial
New York
|
-$104K |
| 4 |
Wells Fargo
San Francisco,
California
|
-$82.5K |
| 5 |
Jane Street
New York
|
-$79K |
ATXI Hedge Fund Activity: Q1 2021 in Review
30 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Avenue Therapeutics, Inc. Common Stock (ATXI) for Q1 2021, worth a combined $11.1M — down 8.9% from $12.2M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of ATXI and 3 opened new positions — a net loss of 3 holders — while 5 trimmed existing stakes and 8 added.
The largest buyer was State Street, adding an estimated $240K. The largest seller was Vanguard Group, cutting an estimated $1.47M.
- 30 institutional investors held Avenue Therapeutics, Inc. Common Stock (ATXI) as of Q1 2021, down from 33 in Q4 2020.
- Funds reported $11.1M of Avenue Therapeutics, Inc. Common Stock stock for Q1 2021, down 8.9% quarter-over-quarter.
- 3 funds opened new Avenue Therapeutics, Inc. Common Stock positions in Q1 2021 and 6 closed out, a net change of -3 holders.
- The largest Avenue Therapeutics, Inc. Common Stock buyer in Q1 2021 was State Street, an estimated $240K added.
- The largest Avenue Therapeutics, Inc. Common Stock seller in Q1 2021 was Vanguard Group, an estimated $1.47M sold.
Based on aggregated 13F filings for Q1 2021.